九典制药(300705) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥568,212,860.39, representing a 42.82% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥78,622,110.11, up 39.41% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥77,176,911.73, reflecting a 46.25% increase from the previous year[5] - The company reported a total of ¥90,259,643.84 in trading financial assets, down from ¥100,314,246.58[18] - The net profit for the third quarter was 208,389,289.18, an increase of 23.1% compared to 169,211,746.27 in the same period last year[32] - Operating profit reached 231,054,782.41, up from 187,884,885.27, reflecting a growth of 22.9% year-over-year[32] - Total revenue from operating activities was 1,740,154,700.95, compared to 1,268,663,192.10, marking a year-over-year increase of 37.1%[33] - The total profit for the period was 230,472,568.29, compared to 187,535,180.75, showing an increase of 22.9% year-over-year[32] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,038,665,448.50, a 16.81% increase from the end of the previous year[5] - The company's total liabilities reached CNY 774,739,577.46, compared to CNY 645,899,203.77, marking an increase of 19.9%[25] - Non-current liabilities rose to CNY 414,086,794.87, up from CNY 275,523,196.97, indicating a 50.4% increase[25] - The equity attributable to shareholders increased to CNY 1,263,925,871.04 from CNY 1,099,337,578.54, a growth of 15%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥166,513,197.28, showing a significant increase of 73.87%[10] - Cash flow from operating activities generated a net amount of 166,513,197.28, compared to 95,766,161.00 in the previous year, indicating a significant improvement[36] - Investment activities resulted in a net cash outflow of -285,124,174.85, compared to -242,069,533.61 in the same period last year[36] Shareholder Information - The top shareholder, Zhu Zhihong, holds 35.75% of shares, totaling 117,474,000 shares[14] - The second-largest shareholder, Duan Lixin, owns 14.78% of shares, amounting to 48,561,005 shares[14] - The company has a total of 10,086 common stock shareholders at the end of the reporting period[14] Research and Development - The company's R&D expenses for the period were ¥128,529,979.49, which is a 41.70% increase due to new R&D projects[10] - Research and development expenses were CNY 128,529,979.49, representing a 41.7% increase from CNY 90,708,588.17 year-over-year[26] Current Assets - Total current assets as of September 30, 2022, amounted to ¥1,070,000,000, a decrease from ¥1,200,000,000 at the beginning of the year[18] - Cash and cash equivalents decreased to ¥322,894,203.81 from ¥398,405,362.65, reflecting a decline of approximately 19%[18] - Accounts receivable increased significantly to ¥370,068,745.49 from ¥248,853,047.33, representing a growth of about 48.5%[18] - Inventory rose to ¥264,520,420.81, up from ¥214,478,519.60, indicating an increase of approximately 23.3%[18] - Other receivables increased to ¥3,151,993.75 from ¥2,150,570.41, marking a rise of approximately 46.5%[18] Operating Costs - Total operating costs amounted to CNY 1,367,842,381.56, up 43.8% from CNY 951,368,579.56 in the prior period[26] - The company reported a significant increase in sales expenses, which totaled CNY 817,858,940.49, up from CNY 567,383,854.88, reflecting a 44.0% rise[26] Credit Impairment - The company experienced a 73.03% increase in credit impairment losses, primarily due to an increase in accounts receivable[10] - The company incurred credit impairment losses of -7,036,771.77, which increased from -4,066,792.83 in the previous year[32]